Given the frequency of aberrant MAPK/ERK activity observed in melanoma, several inhibitors have been developed to target various components of this pathway, including inhibitors of BRAF, MEK and more recently RAS and ERK (reviewed in 30, 31). The gene discussed is MAP2K7; the disease is melanoma.